BioPharma Resources

Drug Trial Radar · NCT05096832

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study

A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

Last checked: Nov 19, 2026Latest source record: Apr 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 10,381 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,381

Actual

Start

Nov 3, 2021

Primary completion

Feb 18, 2022

Study completion Apr 14, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older after the Vaccination of 2 Doses of Inactivated Vaccines

Conditions

  • COVID-19 Pandemic

Interventions

  • Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)Biological

    Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac). Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily

  • Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)Biological

    The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the relative efficacy of recombinant SARS-CoV-2 fusion protein vaccine (V-01) as a booster to prevent symptomatic and RT-PCR positive COVID-19 (mild or above severity)Time frame: From 15days after the administration of recombinant SARS-CoV-2fusion protein vaccine (V-01) to 12 months after full-courseimmunization
  2. The incidence of adverse events (AEs)Time frame: Within 28 days after the booster vaccination

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Sunway Medical Centre Velocity (SMCV) Cheras

    Kuala Lumpur, Malaysia

  • Hospital Pakar Sultanah Fatimah

    Muar town, Malaysia

  • Sunway Medical Centre (SunMed)

    Petaling Jaya, Malaysia

  • Hospital Pulau Pinang

    Pulau Pinang, Malaysia

  • Klinik Kesihatan Seremban 2

    Seremban, Malaysia

  • Seri Manjung Hospital

    Seri Manjung, Malaysia

  • Hospital Sibu

    Sibu, Malaysia

  • Hospital Sultan Abdul Halim

    Sungai Petani, Malaysia

  • Hospital Taiping

    Taiping, Malaysia

  • Sarawak General Hospital

    Kuching, Sarawak, Malaysia

  • Central Hospital Gujranwala

    Gujranwala, Pakistan

  • Shifa International Hospitals

    Islamabad, Pakistan

  • Aga Khan University Hospital

    Karachi, Pakistan

  • Dow University Hospital

    Karachi, Pakistan

  • Sindh Infectious Diseases Hospital & Research Center

    Karachi, Pakistan

  • Al Khidmat Foundation - Surraya Azeem Waqf Hospital

    Lahore, Pakistan

  • Avicenna Dental College

    Lahore, Pakistan

  • Central Park Medical College and Hospital

    Lahore, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.